ABAC Therapeutics and the University of Santiago de Compostela join forces to fight antibiotic-resistant bacteria

draft
infection caused antibiotic resistant bacteria They are one of the largest health problems globally in terms of mortality, social and economic impact.Causes of multidrug-resistant bacteria 1.27 million people die every year And, according to the World Health Organization (WHO), exist Will be the leading cause of death in 2050 Worldwide, it claims more than 10 million lives every year. In this context, the Innopharma drug discovery platform relies on the Center for Molecular Medicine and Chronic Disease Research (citrus) of University of Santiago de Compostelahas reached an agreement with ABAC Therapeutics to join forces to find new treatment solutions.

Multidrug-resistant bacteria kill 39,000 people a year in Europe, and the World Health Organization estimates they will become the world’s leading cause of death by 2050

Specifically, both entities agree to create a mixed unit Allows optimization with maximum efficiency and cost filter A collection of compounds with the purpose of Identifying future antimicrobials Active against drug-resistant bacteria. Antibiotics that helped save millions of lives over the past few decades are no longer effective against these bacteria. Currently, pharmacological research faces the most pressing challenges: New effective antibiotics To treat such infections, in addition, affordable For all the people.

Bacterial resistance to existing antimicrobial drugs is one of The biggest threats to global health Problems facing humanity in the 21st century. “The so-called silent pandemic knows no borders, with multidrug-resistant bacteria killing 39,000 people in Europe every year. Furthermore, this very serious human disaster has had a significant social and economic impact, costing approximately €1.5 billion per year in Europe alone.“, pointed out Domingo Gargallo-ViolaABAC Therapy Director.

Gargallo-Viola (ABAC Therpeutics): “This very serious human catastrophe has had a significant social and economic impact, with an annual impact of approximately 1.5 billion euros in Europe alone”

Bacteria become resistant because they are able to mutate and adapt in response to adverse conditions (among other reasons).l Abuse of antibiotics

, allowing some bacteria to escape its influence. This complicates the treatment of increasingly common and difficult-to-treat infections in the clinic, such as pneumonia, tuberculosis, sepsis, or gonorrhea.

“In the face of drug resistance, there is an urgent need to discover and develop new antibiotics, and to this end, we want to screen a variety of compounds with the aim of Identifying new drugs against drug-resistant bacteria. “Only a strategy based on the medium to long term can address this serious global health problem.”express Mabel LotharPlatform Director at CiMUS and Innopharma.

Mabel Loz (Cimus): “In the face of drug resistance, there is an urgent need to discover and develop new antibiotics”

Pioneer unit with the highest security conditions

In order to study living pathogenic microorganisms, pharmacologists must work with these drug-resistant bacteria, which means a laboratory with the highest safety conditions is required, in which these dangerous microorganisms Handled safely with expertise and technology. The new partner, ABAC Therapeutics, has the appropriate facilities and experience in handling drug-resistant bacteria. For its part, the Innopharma platform has extensive experience and unique infrastructure in Spain, enabling the fully automated management of millions of compounds.

Therefore, the collaborative unit between ABAC Therapeutics and Innopharma-USC Platform represents strategic opportunities Address the challenge of identifying new compounds effective against these organisms and provide new treatment solutions for patients infected by pathogens that are resistant to existing antibiotics.Furthermore, it constitutes a reference in Europe and opens the door to The addition of new collaboratorsCollaboratively and effectively promote the urgent search for antimicrobials to combat this global silent epidemic, ensuring that these new treatments are available to all who need them.